Key result
New oral anticoagulants are not recommended for widespread use in preventing and treating tumor-associated VTE prior to phase III trials due to a lack of efficacy and safety data.
Why the study?
Are new oral anticoagulants safe and effective for the prevention and treatment of venous thromboembolism in cancer patients receiving chemotherapy?
Are new oral anticoagulants safe and effective for the prevention and treatment of venous thromboembolism in cancer patients receiving chemotherapy?
The use of NOACs in cancer patients undergoing chemotherapy requires further phase III trial data before widespread adoption can be recommended.
Answers are grounded in this paper and cite their sources.
Defer NOAC use for tumor-associated VTE until phase III data; leaves open their role in cancer patients.
Despite large number of known risk factors of venous thromboembolism (VTE) in cancer patients existing prediction models do not allow definite identification of cancer patients that have indications for anticoagulant prevention. Besides, heparin and warfarin use for VTE prevention in cancer is accompanied by some problems. New oral anticoagulants (NOAC) are promising drugs for use in oncology practice; however their use is complicated by the lack of data on efficacy and safety in these patients, potential drug interactions and the possibility of unpredictable changes in effect during chemotherapy. Widespread use of NOAC for the prevention and treatment of tumor-associated VTE prior to phase III trials is not recommended. However, the criteria for selection of patients for whom the study of the efficacy and safety of NOAC is a priority can now be developed.
No takes yet. Share an insight, caveat, or question.
Rumyantsev et al. (2014) conducted a review in Venous thromboembolism (VTE) in cancer patients receiving chemotherapy. New oral anticoagulants (NOAC) was evaluated. New oral anticoagulants are not recommended for widespread use in preventing and treating tumor-associated VTE prior to phase III trials due to a lack of efficacy and safety data.
Synapse has enriched 10 related papers. Consider them for comparative context: